Boehringer Ingelheim Licenses Owkin’s K Pro AI Scientist and Patient Data

Owkin has licensed its AI Scientist platform K Pro and multimodal oncology and immunology patient data to Boehringer Ingelheim to accelerate biopharma research. The deal builds on a 2025 pilot using Owkin's MOSAIC spatial multiomics cancer dataset. Boehringer's teams will use K Pro to analyze data and generate hypotheses in oncology and immunology research.